(Q44609997)

4 December 2017

Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy (English)

1 reference

4 December 2017

4

1 reference

4 December 2017

Julia A Johnson

1

1 reference

4 December 2017

Jeanine B Albu

2

1 reference

4 December 2017

Ellen S Engelson

3

1 reference

4 December 2017

Yoritaro Inada

5

1 reference

4 December 2017

Gabriel Ionescu

6

1 reference

4 December 2017

Donald P Kotler

7

1 reference

4 December 2017

language of work or name

1 reference

7 October 2003

1 reference

American Journal of Physiology - Endocrinology and Metabolism

4 December 2017

1 reference

4 December 2017

286

1 reference

4 December 2017

E261-71

1 reference

4 December 2017

2

1 reference

Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women.

4 December 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Soluble tumour necrosis factor alpha receptor 2, a serum marker of resistance to the anabolic actions of growth hormone in subjects with HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Soluble receptors for tumor necrosis factor are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Impaired insulin action in subcutaneous adipocytes from women with visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Role of "local" hormones in regulation of lipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

"Buffalo hump" in men with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

Inhibition of adipocyte differentiation by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

TNFα expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00056.2003

10.1152/AJPENDO.00056.2003

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference